44 results about "Encephalitis Viruses" patented technology

This invention involves, among other things, elements that stimulate an immune response. Which includes: a) one or more antigens of Avibacterium paragallinarum and One or more antigens of avian brain and spinal cord rhizomatous virus and one antigen. or more of avian porcine ... Furthermore, this invention relates to a method for immunizing animals which includes administration. The animal drug contains components that stimulate the immune response of this invention; moreover, This invention relates to a method of treating or preventing clinical signs caused by Avibactericum. Paragallinarum, a viral infection that causes encephalitis and spinal cord inflammation in birds and avian pox virus in animals. Essential, a method that involves administering medication to animals in effective dosages as a form of treatment. The components that stimulate an immune response are consistent with this invention;

The invention belongs to the technical field of virus detection, and particularly relates to a primer probe composition for detecting Japanese encephalitis virus and application, the primer probe composition comprises a probe, an upstream primer and a downstream primer, the nucleotide sequence of the upstream primer is shown as SEQ ID No.3, and the nucleotide sequence of the downstream primer is shown as SEQ ID No.6. According to the primer probe composition, the invention provides a non-diagnostic method for detecting the Japanese encephalitis virus, and the method has the advantages of rapidness, real time, strong specificity, high sensitivity, simplicity and convenience in operation and suitability for various fluorescence detection equipment, and can accurately detect the Japanese encephalitis virus from a sample to be detected.

This invention relates to the field of pharmaceutical technology, specifically the application of NEDD8 activator in the preparation of drugs for treating Japanese encephalitis. Using human neuroblastoma cells (SH-SY5Y) as target cells, this invention utilizes activators from a library of ubiquitinated compounds to target and activate key enzymes in the ubiquitination pathway, aiming to identify host factors associated with Japanese encephalitis virus (JEV) infection of SH-SY5Y cells. This helps to understand the mechanism by which JEV invades the central nervous system and causes neuronal cell damage, and also provides new targets for therapeutic drugs against JEV-induced Japanese encephalitis. This invention experimentally discovered that NEDD8 activator (NAE) has the property of inhibiting JEV infection of SH-SY5Y cells. This invention provides the application of NEDD8 activator in the preparation of drugs for treating Japanese encephalitis, offering new targets and treatment strategies for the prevention and treatment of JEV.

The present application relates to the field of biological medicine, in particular to a kind of muscone in the application of viral inhibitor.The viral inhibitor of the present application is used to inhibit the replication of Japanese encephalitis virus and / or porcine epidemic diarrhea virus.The present application finds that muscone has no cytotoxicity, and does not directly inactivate virus, but produces antiviral effect on Japanese encephalitis virus by inhibiting NLRP3 / Caspase-1, Caspase-9 / Caspase-3 / Bax / BCL-2, JNK / ERK / P38 and other signal pathways, and inhibits porcine epidemic diarrhea virus invasion into cells by reducing caveolin level.The antiviral effect is remarkable, the mechanism of action is clear, the selectivity is high, and the safety is better.

This invention relates to the field of pharmaceutical technology, specifically the application of NEDD8 activator enzyme inhibitors or their hydrochlorides in the preparation of drugs for treating Japanese encephalitis. This invention utilizes inhibitors from a library of ubiquitinated compounds to target and inhibit key enzymes in the ubiquitination pathway, aiming to identify host factors associated with Japanese encephalitis virus (JEV) infection of SH-SY5Y cells. This contributes to understanding the mechanism by which JEV invades the central nervous system and causes neuronal cell damage, and also provides new targets for therapeutic drugs against JEV-induced Japanese encephalitis. This invention discovers that NEDD8 activator enzyme (NAE) inhibitors or their hydrochlorides possess the property of inhibiting JEV infection of SH-SY5Y cells. This invention provides the application of NEDD8 activator enzyme inhibitors or their hydrochlorides in the preparation of drugs for treating Japanese encephalitis, offering new targets and therapeutic strategies for the prevention and treatment of JEV.

The invention provides a brain organoid / encephalitis B virus infected brain organoid model and a construction method and application thereof, and belongs to the technical field of organoid. The invention provides the kit for constructing the brain organoid, the brain organoid is constructed on the basis of the kit, the construction method of the brain organoid is provided, and the constructed brain organoid model shows clear staged development characteristics, completely reproduces cell diversity in the human brain development process and forms ventricular-like structural characteristics. The encephalitis B virus infected brain organ model constructed on the basis of the obtained brain organs can be used for deeply analyzing the pathogenic process and related immune response characteristics of JEV infected human brain, researching and developing vaccines related to encephalitis B virus and screening antiviral drugs.

The application discloses a recombinant getah virus expressing E protein of Japanese encephalitis virus, the virus has the E protein gene of the Japanese encephalitis virus, and the E protein gene is located between Cap and E3 genes of the genome of the getah virus. A corresponding construction method is also established, the getah virus is used as a parent strain, an infectious clone pGETV-GV thereof is used as a carrier, a truncated E protein of the Japanese encephalitis virus is inserted between Cap and E3 by using a genetic engineering method, and the recombinant getah virus rGECJEV-E is obtained. Tests show that the recombinant getah virus rGECJEV-E has the characteristics of good performance, good stability and high expression amount of exogenous protein, the expressed protein has good immunogenicity, can provide immunoprotection for the attack of the Japanese encephalitis virus, and the safety of the recombinant strain is relatively high. Therefore, the recombinant virus has great potential in preparation of a vaccine or a medicine for preventing or treating the getah virus and / or the Japanese encephalitis virus, and is expected to develop a recombinant bivalent vaccine for the getah virus and the Japanese encephalitis.

The invention relates to the field of biological medicine, in particular to application of muscone in preparation of a virus inhibitor. The virus inhibitor is used for inhibiting replication of Japanese encephalitis virus and / or porcine epidemic diarrhea virus. It is found that muscone has no cytotoxicity, does not directly inactivate viruses, generates an antiviral effect on Japanese encephalitis viruses by inhibiting signal channels such as NLRP3 / Caspase-1, Caspase-9 / Caspase-3 / Bax / BCL-2, JNK / ERK / P38 and the like, and inhibits porcine epidemic diarrhea viruses from invading cells by reducing the level of litter protein. The antiviral effect is obvious, the action mechanism is clear, the selectivity is high, and the safety is better.

The invention belongs to the technical field of virus detection, and particularly relates to a dual-channel real-time fluorescent quantitative PCR (polymerase chain reaction) detection primer, a probe, a detection kit, a detection method and an application of the dual-channel real-time fluorescent quantitative PCR detection primer. Comprising specific primers of the Intity cereal encephalitis virus (Australian encephalitis virus) as shown in SEQ ID NO.1-2 and a probe of the Intity cereal encephalitis virus as shown in SEQ ID NO.3. The detection sensitivity is high, and the lowest detection limit can reach 8 copies / mL; the detection time period is short, nucleic acid detection can be completed within 40 minutes, and the kit is suitable for clinical and bedside rapid detection and diagnosis; the detection specificity is high, and cross amplification with other 80 pathogens is avoided; the detection accuracy is 100%; virus quantitative analysis can be carried out, and the quantitative linear range is good; the detection repeatability is good, and the precision is high.

The disclosure provides a Japanese encephalitis virus transmission risk estimation method and device and electronic equipment, relating to the technical field of disease transmission, the method comprises the steps of: determining a first infection force model, a second infection force model, a first incidence overflow rate model and a second incidence overflow rate model based on mosquito vector data, host infection kinetics data and host data corresponding to a first time interval; estimating the contribution coefficient of vertical transmission basic infection force and mosquito ovitraps index to the infection force of mosquito vector transmission to the host based on the first infection force model and the second infection force model; estimating the intensity coefficient based on the first incidence overflow rate model and the second incidence overflow rate model; estimating the host data of the second time interval based on the vertical transmission basic infection force, the contribution coefficient of the mosquito ovitraps index to the infection force and the intensity coefficient; in this way, the whole chain quantitative evaluation from mosquito vector to host and from host to host can be realized, and the risk evaluation accuracy of host infection virus in a real scene is improved.

The invention relates to the technical field of nucleic acid molecule detection, and particularly discloses a kit for detecting forest encephalitis virus nucleic acid through an RT-MIRA / Cas12a one-step method and application thereof.According to the method, total RNA extracted from ticks or infected blood samples serves as a template, target sequence amplification is conducted through the RT-MIRA / Cas12a rapid amplification technology, then the target sequence is assembled with Cas12a protein and crRNA to form a compound, and the target sequence is detected through an RT-MIRA / Cas12a one-step method. And activating the excision activity of Cas12a, and cutting the free single-stranded DNA probe in the system. According to the detection result, visual fluorescence can be observed through naked eyes under an ultraviolet light source or a blue light source, or generation of a red strip at the position of a detection line is observed through a CRISPR single system detection test strip. The method has good specificity on the forest encephalitis virus, and has no cross reaction with other tick-borne viruses, parasites and common bacteria; the kit has the advantages of simplicity and convenience in operation, rapidness in detection, intuitive result, high sensitivity and the like, and an efficient tool is provided for on-site rapid screening and epidemiological monitoring of the forest encephalitis virus.

The invention discloses a detection system for visually detecting a swine Japanese encephalitis virus based on an RT-RAA-CRISPR / Cas12a system, and the visual detection of the JEV is realized by designing crRNA and RAA amplification primers for a JEV NS1 gene conserved region and triggering the breakage of a double-labeled ssDNA reporter molecule by using the specific recognition and trans-cleavage activity of Cas12a protein to an RAA amplification product. The lower detection limit of the method is 2.04 * 10 < 0 > copies / [mu] L; the clinical sample detection rate is 61.0% and is equivalent to that of 63.4% of PCR (Polymerase Chain Reaction). Therefore, the invention establishes a nucleic acid diagnosis method with strong specificity, high sensitivity, short detection time and simple operation, and the method is also suitable for pig farm on-site epidemic situation screening, animal quarantine ports, grassroots veterinary stations, remote area public health monitoring and other aspects.

The invention discloses a monoclonal antibody of Japanese encephalitis virus and Zika virus and application of the monoclonal antibody, and belongs to the technical field of immunology and molecular virology. The monoclonal antibody or the antigen binding fragment thereof comprises VH CDR1, VH CDR2 and VH CDR3 of which the amino acid sequences are shown as SEQ ID NO: 1-3, and VL CDR1 and VL CDR3 of which the amino acid sequences are shown as SEQ ID NO: 4 and SEQ ID NO: 5, and the amino acid sequence is VL CDR2 of AAS. The monoclonal antibody LZY2086 provided by the invention can be combined with E protein extracellular regions of the encephalitis B virus and the Zika virus with high affinity, and has very strong neutralizing activity on the encephalitis B virus and the Zika virus. Therefore, as a broad-spectrum neutralizing antibody, the monoclonal antibody LZY2086 disclosed by the invention has ideal clinical application value in prevention and treatment of Japanese encephalitis virus and Zika virus infection.

The application discloses application of a host PRKCSH gene as a target point in prevention and treatment of various RNA virus infections. Experiments prove that knocking out the PRKCSH gene of a pig can significantly inhibit adhesion and invasion of Japanese B encephalitis virus to a host cell, and can also significantly inhibit replication of a classical swine fever virus, a porcine transmissible gastroenteritis virus, a Senecavirus, a porcine epidemic diarrhea virus and a porcine reproductive and respiratory syndrome virus in the host cell. In addition, knocking out the PRKCSH gene of a human can significantly inhibit replication of the Japanese B encephalitis virus in the host cell. Therefore, specific targeted editing of the PRKCSH gene or interference with protein expression of the PRKCSH gene can inhibit infection of various RNA viruses to host cells.

The invention relates to compounds that are inhibitors of Flavivirus NS2B-NS3 proteases and inhibit replication of flavivirus in cells. Compounds of this invention are useful alone or in combination with other agents for use in the treatment of infections caused by Flaviviruses, in particular by Dengue, West Nile, Zika, Japan Encephalitis viruses.

The invention provides application of a sarcodia montagneana extract in preparation of a composition for inhibiting Japanese encephalitis virus. Wherein the sarcodia montagneana extract is extracted from a sarcodia montagneana frond material or a sarcodia montagneana frond, the sarcodia montagneana extract contains a component for inhibiting the Japanese encephalitis virus, the sarcodia montagneana extract can be applied to resisting infection of the Japanese encephalitis virus and inhibiting the activity of the Japanese encephalitis virus, and the sarcodia montagneana extract does not have cytotoxicity.

The invention discloses application of KML29 in preparation of a medicine for inhibiting Japanese encephalitis virus infection, discovers that KML29 can significantly inhibit Japanese encephalitis virus replication, and discovers that KML29 not only inhibits transcription of Japanese encephalitis virus, but also can reduce expression of NS5 protein. Therefore, the KML29 can be used for preventing or treating the Japanese encephalitis virus.

The application provides a recombinant protein and a construction method and application in tick-borne encephalitis virus vaccine thereof, and the amino acid sequence of the recombinant protein is shown as SEQ ID NO. 2. A novel tick-borne encephalitis virus nano vaccine EDIII-Fd-F nanoparticle is prepared by using a phage-derived Foldon scaffold protein to assist the third domain (TBEV-EDIII) peptide segment of a tick-borne encephalitis virus envelope protein to form a trimer form, and then displaying on the surface of a recombinant human heavy chain ferritin cage structure. The nano particle can protect mice from lethal dose infection of different subtypes of tick-borne encephalitis virus, is simple to prepare, does not involve live virus culture, is safe, has high product yield, and is suitable for large-scale production.

The application provides a hybridoma cell strain, the preservation number of the hybridoma cell strain is CCTCC NO: C2024394, and the hybridoma cell strain is prepared from spleen lymphocytes of mice immunized by a vaccine containing a recombinant protein with an amino acid sequence as shown in SEQ ID NO. 1. Further, the hybridoma cell is used to prepare a monoclonal antibody V6-M15 which can be highly specific to bind to a trimer conformation in a membrane fusion process of EDIII, and the monoclonal antibody V6-M15 can effectively inhibit the amplification of three TBEV, and can provide broad-spectrum protection against three TBEV subtype strains. The application provides a new strategy for developing more effective TBEV specific monoclonal antibodies and prevention and treatment of TBEV.

The invention belongs to the field of development of antiviral drugs, and particularly relates to application of LEI-401 in preparation of drugs for resisting epidemic encephalitis B virus infection. The CAS number of the LEI-401 is 2393840-15-6, the invention discloses that the LEI-401 can obviously inhibit Japanese encephalitis virus replication and reduce virus load for the first time, and proves that the LEI-401 can improve the survival rate of infected mice, has good antiviral activity and safety in an animal model, and can be used for developing drugs for treating or preventing epidemic Japanese encephalitis virus infection. The invention also provides a suspension for resisting epidemic encephalitis B virus infection. The suspension has the advantages of safety, high efficiency and wide application prospect.

The application provides application of embelin in preparation of a medicine for resisting St. Louis encephalitis virus infection. The application has the beneficial effect that the embelin has significant inhibitory effect on NS2B-NS3 protease activity in the St. Louis encephalitis virus, can be used as an inhibitor of the NS2B-NS3 protease in the St. Louis encephalitis virus, and is expected to become a potential medicine for resisting St. Louis encephalitis virus infection.

This invention discloses labeled antibodies and related biological materials, and their application in the detection of tick-borne encephalitis virus (TEV). The application includes any of the following: (1) preparing products for detecting TEV; (2) preparing products binding to the TEV E protein; (3) detecting TEV; and (4) binding to the TEV E protein. Compared with traditional HRP-labeled antibodies, this labeled antibody has higher detection sensitivity.

This invention relates to the field of pharmaceutical technology, specifically the application of deubiquitinase USP20 inhibitors in the preparation of drugs for treating Japanese encephalitis. This invention uses human neuroblastoma cells (SH-SY5Y) as target cells and utilizes inhibitors from a library of ubiquitination compounds to target and inhibit key enzymes in the ubiquitination pathway, aiming to identify host factors associated with Japanese encephalitis virus (JEV) infection of SH-SY5Y cells. This helps to understand the mechanism by which JEV invades the central nervous system and causes neuronal cell damage, and also provides new targets for therapeutic drugs against JEV-induced Japanese encephalitis. This invention experimentally demonstrated that deubiquitinase USP20 inhibitors have the property of inhibiting JEV infection of SH-SY5Y cells. This invention provides the application of deubiquitinase USP20 inhibitors in the preparation of drugs for treating Japanese encephalitis, offering new targets and treatment strategies for the prevention and treatment of JEV.

The application belongs to the technical field of molecular biology, and particularly relates to application of antibacterial peptide WK-13-3D in preparation of a medicine for inhibiting Japanese encephalitis virus infection. 50 The application surprisingly finds that the antibacterial peptide WK-13-3D can significantly reduce the production of JEV RNA in a dose-dependent manner, inhibit the expression of JEV non-structural protein NS3, significantly reduce the yield of infectious JEV, inhibit the adhesion of JEV to host cells, and the IC 50 value of the antiviral activity is 2.339 micromoles, the antibacterial peptide WK-13-3D can inhibit the infection of Japanese encephalitis virus, can be used as a medicine for treating Japanese encephalitis virus infection, and has a good application prospect.

The invention provides a tick-borne encephalitis virus monoclonal antibody and application thereof, and relates to the field of biotechnology and virology. A mouse monoclonal antibody mAb-16 with specific neutralizing activity is screened, the monoclonal antibody mAb-16 mainly aims at envelope protein E of tick-borne encephalitis virus, the monoclonal antibody mAb-16 can specifically recognize and neutralize domain III in E protein EDIII of tick-borne encephalitis virus, and a biological membrane layer interference experiment shows that the monoclonal antibody mAb-16 has relatively strong interaction with the domain III of the E protein. The median inhibition concentration of the monoclonal antibody mAb-16 on primary viruses cultured by sensitive cells is 92.80 ng / mL; in a lethal mouse infection model, a high-dose group has complete protection activity and can be used for preparing tick-borne encephalitis virus detection reagents or related drugs for neutralizing and inhibiting tick-borne encephalitis viruses, so that prevention and treatment of tick-borne encephalitis viruses are facilitated.

The first aspect of the invention relates to the amino acid sequence of the recombinant virus-like particles (VLPs) shown as the sequence number SEQ 1, based on the natural TBEV proteins: the prM and E protein. The change in the sequence of natural proteins refers, inter alia, to the introduction of additional modified sequences into the sequence of natural proteins, i.e., the signal sequence for LMSAP1 phosphatase from Leishmania mexicana, e.g., the signal sequence from the LEXSinduce3 Expression Kit expression system and P2A sequence, which result in more efficient overproduction of VLPs and increase their immunogenicity. A second aspect of the invention relates to recombinant VLPs with the amino acid sequence according to the invention (SEQ 1) for medical use in the prevention and control of tick-borne encephalitis, especially when used in a form of a vaccine component.

The present invention relates to high titer Japanese encephalitis virus genotype 5 and uses thereof, and specifically relates to a high titer virus produced using subculture and mouse cerebral inoculation methods and a vaccine composition comprising the same.

The invention discloses a vaccine for preventing and treating swine Japanese encephalitis virus and application, and belongs to the field of biological pharmacy for livestock. The CHO stable expression cell line expressing the E protein Domain III is constructed, transcription and protein expression levels are remarkably improved, the cell line grows under the glutamine-free condition, accumulation of metabolites such as ammonia is reduced, and cell activity and long-term culture stability are improved. The FC fusion protein is added after the ED3 gene sequence through the flexible Linker, so that the affinity chromatography purification process is simplified, the recovery rate and the purity are improved, and the production cost is reduced; meanwhile, the high-efficiency expression of CHO cells is combined, so that the purified protein yield is higher than 2g / L, which is far better than that of a traditional method, and the large-scale requirement of veterinary vaccines is met. The vaccine provided by the invention has no pathogen residual risk, the safety is higher than that of the traditional inactivated or attenuated live vaccine, and the vaccine which is safe, reliable and good in immunogenicity is provided for preventing and treating infection of the swine Japanese encephalitis virus.

The invention discloses an ELISA detection kit for detecting forest encephalitis virus envelope E protein, and relates to the technical field of kits. The kit comprises a pre-coated elisa plate, an elisa antibody, a TBEV E protein quantitative standard substance, a sample diluent, a 20-time concentrated washing solution, a chromogenic substrate A, a chromogenic substrate B, a stop buffer, a plate sealing film and a drying agent. According to the present invention, the totivirus specific correlation can be identified, and the method can be used for the preparation of the kit quality control product so as to achieve the quantitative detection, and is suitable for the E protein preparation and the identification of the specific virus protein monoclonal antibody.

The invention provides a Japanese encephalitis virus transmission risk estimation method and device and electronic equipment, and relates to the technical field of disease transmission, and the method comprises the steps: storing main infection dynamics data and host data based on mosquito-borne data corresponding to a first time interval, determining a first infection model, a second infection model, a first disease overflow rate model and a second disease overflow rate model; estimating the contribution coefficient of the vertical propagation basic infectivity and the mosquito-borne egg trap index to the infectivity of mosquito-borne propagation to the main storage body based on the first infectivity model and the second infectivity model; estimating an intensity coefficient based on the first disease overflow rate model and the second disease overflow rate model; estimating host data in a second time interval based on the vertical propagation basic infectivity, the contribution coefficient of the mosquito-borne egg trap index to the infectivity and the strength coefficient; therefore, full-chain quantitative evaluation from mosquito vector to storage host and from storage host to host can be realized, and the risk evaluation precision of host virus infection in a real scene is improved.